Key Takeaways
  • KPV is not an FDA approved drug. There is no approved KPV product, no approved labeling and no approved indication in the United States.
  • On October 28, 2026, HHS issued an enforcement discretion policy, published in the Federal Register on October 30, 2026 under docket HHS-OASH-2026-0496, stating that it does not intend to act against a state-licensed pharmacy, a federal facility or a licensed physician compounding KPV acetate when all listed conditions are met.
  • For KPV, the policy addresses topical and oral forms only. It does not describe an injectable route for this peptide.
  • Every condition must be satisfied together: a patient-specific prescription, a single active ingredient, an FDA-registered and CGMP-compliant original manufacturer with its facility location on the certificate of analysis, testing consistent with Appendix B, MedWatch reporting, the label statement "This is a compounded drug product. Not for resale.", and an FDA 510(k)-cleared syringe as the only co-packaged device.
  • Enforcement discretion is not approval and is not an addition to the 503A bulks list. FDA's Center for Drug Evaluation and Research had recommended against listing these substances.
  • The policy is interim and revocable, it excludes research-use-only material and 503B outsourcing facilities, and it changes nothing outside the United States.
  • This page is educational only. It is not medical advice and contains no instructions for use.

Is KPV an FDA approved drug in the United States?

No. KPV is not approved by the U.S. Food and Drug Administration. There is no approved KPV product, no FDA-approved labeling, no approved indication and no approved manufacturer. Anyone describing KPV as an approved medicine in the United States is describing something that does not exist.

What changed in late 2026 is narrower, and it is easy to misread. On October 28, 2026, the Department of Health and Human Services issued an enforcement discretion policy covering the use of certain peptide bulk drug substances in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. A notice describing that policy was published in the Federal Register on October 30, 2026 (Volume 91, Issue 209) under docket number HHS-OASH-2026-0496, with a public comment period running through November 13, 2026.

Under that policy, HHS states that it does not intend to take action against a state-licensed pharmacy, a federal facility or a licensed physician who compounds a drug product using KPV acetate, for topical and oral forms, provided that all of the listed conditions are met. The word that carries the weight here is "all". These are cumulative requirements, not a menu.

Enforcement discretion and approval are two different legal concepts. Approval means a sponsor submitted an application, FDA reviewed evidence of safety and effectiveness, and the agency authorized a specific product for a specific use. Enforcement discretion means a federal agency is stating, for now, how it intends to exercise its own enforcement resources. It confers no finding that a product works, and it can be narrowed or withdrawn.

This page covers only the prescription and pharmacy compounding route in the United States. For the general background on the molecule itself, see the KPV peptide guide, and for the wider legal picture across product categories and jurisdictions, see are peptides legal. This article is for educational purposes only and is not medical advice. Consult a healthcare professional about any individual situation.

What did HHS actually announce in October 2026?

The policy sits inside a long-running regulatory process. Section 503A of the Federal Food, Drug, and Cosmetic Act allows a compounder to use a bulk drug substance only under defined circumstances, one of which is that the substance appears on a list established by FDA through rulemaking, commonly called the 503A bulks list. That rulemaking is still in progress. The October 2026 HHS policy is explicitly an interim measure for the period while it continues.

The policy addresses six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Each is identified in the policy's appendices by a specific chemical identity and a specific permitted route of administration, so the six are not treated identically. KPV is identified as KPV acetate.

HHS also stated a reason for acting. The policy is intended to discourage the continued, widespread use of peptides labeled "research use only" and supplied by foreign manufacturers, which HHS described as posing a safety risk to US patients. In other words, the stated goal is to move demand toward supervised pharmacy preparation and away from unregulated material, not to endorse the peptides themselves.

Three categories of compounder are named: a state-licensed pharmacy, a federal facility, and a licensed physician. If an entity does not fall into one of those categories, the policy does not describe it. State pharmacy law continues to apply in full on top of the federal position, and state requirements can be stricter.

Because the notice was published for comment, the text as written in October 2026 is what HHS has described, and it may be revised. Anyone relying on it professionally should read the Federal Register notice and the appendices in full rather than any summary, including this one.

Which KPV forms does the policy cover?

Appendix B of the policy sets out, for each substance, the peptide identity (including amino acid sequence, chemical structure, molecular weight and molecular formula) together with limits on the route of administration. A compounded product that falls outside those identity and route limits falls outside the policy entirely.

For KPV, the identity is the tripeptide Lys-Pro-Val, which corresponds to residues 11 to 13 of alpha-melanocyte-stimulating hormone and is catalogued in PubChem as MSH (11-13), free base formula C₁₆H₃₀N₄O₄ with a molecular weight of approximately 342.4 g/mol. The substance named in the policy is the acetate salt.

The permitted routes for KPV acetate are topical and oral. That is a meaningful difference from several of the other listed peptides. The policy does not describe an injectable route for KPV, so a compounded injectable KPV preparation is not covered by the enforcement position, whatever else is true about how it was made.

This also means that a product combining KPV with another active peptide is outside the policy, because a separate condition restricts covered products to a single active pharmaceutical ingredient. Multi-peptide blends, however they are marketed, are not described by this enforcement position.

None of this speaks to whether KPV works for anything. The human evidence base is thin. The published work most often cited is preclinical: Dalmasso and colleagues reported in Gastroenterology in 2008 that orally administered KPV reduced the incidence of chemically induced colitis in mice through PepT1-mediated uptake, and Kannengiesser and colleagues reported anti-inflammatory effects in two murine colitis models the same year. Animal findings do not establish safety or effectiveness in people, and the HHS policy makes no claim that they do.

What conditions must all be met for the policy to apply?

The policy lists ten conditions. Enforcement discretion is described as available only when every one of them is satisfied for the specific product given to the specific patient. Missing a single item removes the product from the policy's scope.

1. Listed substanceThe active ingredient is one of the peptide bulk drug substances identified in the policy's appendix.
2. Identity and routeThe peptide matches the identity and the route of administration described in Appendix B. For KPV acetate: topical and oral.
3. Registered source and certificateThe bulk substance comes from an establishment registered with FDA and is accompanied by a valid certificate of analysis with testing consistent with the criteria referenced in the policy.
4. Original manufacturerThe original manufacturer is FDA-registered, complies with CGMP, and its physical manufacturing facility location appears on the certificate of analysis given to the compounder. Where a registered repacker, relabeler or reseller is involved, that intermediary must have performed and documented vendor and certificate validation.
5. ReportingThe compounder reports serious adverse events and product quality issues to FDA's MedWatch program and to the relevant states, and provides patient reporting instructions.
6. Label statementThe labeling states: "This is a compounded drug product. Not for resale."
7. Single active ingredientThe compounded product contains only one active pharmaceutical ingredient from the appendix. No blends.
8. Oral documentationFor an oral preparation, the compounder holds documentation that the specific formulation achieves adequate oral bioavailability in humans.
9. Device limitThe only drug delivery device co-packaged with or containing the product is an FDA 510(k)-cleared syringe.
10. All other legal requirementsThe product is compounded in compliance with all other applicable requirements, including the prohibition on compounding under insanitary conditions, section 503A's prescription requirement, and state compounding pharmacy law.

Condition 10 carries the item most relevant to a patient: section 503A compounding requires a valid prescription for an identified individual patient. There is no version of this policy that covers compounding for stock, for distribution, or for a customer who has not been evaluated by a prescriber.

Condition 6 is equally pointed. A product that must be labeled "not for resale" is, by definition, not a commercial article to be passed along a chain. The label text is an instruction about the product's place in the system, not a formality.

How must the KPV substance be sourced and documented?

The sourcing conditions are the most technically demanding part of the policy, and they are where most non-compliant supply would fail. The bulk drug substance must be manufactured by an establishment registered with FDA under section 510 of the Federal Food, Drug, and Cosmetic Act, and it must arrive with a valid certificate of analysis.

The policy is specific that the requirement attaches to the original manufacturer, not to a later packer, repacker, relabeler or distributor. That original manufacturer must be registered, must comply with current good manufacturing practice, and must have the physical location of its manufacturing facility identified on the certificate of analysis provided to the compounder. A certificate that names a trading company, a brand, or a jurisdiction without a facility address does not satisfy the condition as written.

The certificate itself must characterize and identify the substance and include test results consistent with the criteria described in Appendix B, which sets out the identity parameters (amino acid sequence, chemical structure, molecular weight, molecular formula) and the associated testing expectations. In practice that means lot-level testing covering identity, purity and potency, along with contaminant testing such as endotoxins, heavy metals and microbial limits.

Where the substance passes through an FDA-registered repacker, relabeler or reseller, the policy expects that intermediary to have performed and documented appropriate vendor validation of the manufacturer and validation of the manufacturer's certificate of analysis. The chain of custody is part of the condition, not an optional best practice.

This is the clearest practical difference between a compounded preparation and material sold as a chemical. A research-use-only vial does not come with an FDA-registered CGMP manufacturer, a facility address on the certificate, or a pharmacy that tested the lot it dispensed. The broader safety framing is covered in are peptides safe.

What does the policy require for an oral preparation?

KPV is one of only two substances in the policy for which an oral form is addressed at all, and the oral route carries an extra condition that does not apply to topical products.

If the peptide is compounded in an oral form, the compounder is expected to hold documentation confirming that the specific formulation provided to the patient achieves an adequate level of oral bioavailability in humans. The requirement is formulation-specific and species-specific on both counts.

That wording closes two common shortcuts. A study of a different oral formulation does not satisfy it, because absorption of a peptide depends heavily on the excipients, the protection strategy and the delivery system around it. And a general statement that peptides can be absorbed orally, or a result obtained in animals, does not satisfy it either, because the condition names humans.

This matters for a tripeptide specifically. Short peptides face gastric acid, luminal and brush-border peptidases, and limited permeability before they can reach a systemic compartment. Mechanisms such as intestinal peptide transporter uptake have been described in preclinical work, but a mechanism being plausible is not the same as a finished formulation having measured human bioavailability. The condition places the burden of that documentation squarely on the compounder.

For a patient, this condition is a usable question rather than an abstraction. A pharmacy that compounds an oral KPV preparation under this policy should be able to say what documentation it holds for that exact formulation. If the answer is a general reference to published peptide literature, the condition as written has not been addressed.

Why does the policy allow only a 510(k)-cleared syringe?

One condition concerns hardware rather than chemistry: the only drug delivery device co-packaged with or containing the compounded product may be an FDA 510(k)-cleared syringe. HHS framed the restriction in terms of risk, noting that more complex drug delivery devices introduce additional patient risk.

Read literally, that condition excludes pens and auto-injectors, along with other complex delivery systems such as nasal spray devices and pumps. A pen is a combination product in which the device contributes materially to how much drug is delivered and how reliably; that is precisely the added complexity the condition is written to keep out of an interim compounding policy.

For KPV the device condition is mostly academic, because the policy addresses topical and oral forms for this peptide rather than an injectable one. It still matters for anyone comparing peptides across the list, and it matters as a signal about how the policy is drafted: the conditions are narrow by design and are not meant to be extended by analogy.

It is worth separating two things the device condition does not do. It does not approve any device for use with KPV, and it does not endorse any particular presentation. It only describes the single packaging arrangement that stays inside the enforcement position.

What does this policy not change?

The limits are as important as the permissions, and several are stated explicitly in the policy documents.

  • It is not an approval. KPV remains an unapproved drug substance. No efficacy finding, no safety finding and no indication follow from the policy.
  • It is not an addition to the 503A bulks list. The policy does not place KPV or any other listed peptide on that list. Eligibility will be settled by rulemaking, and the enforcement position is described as lasting until a final rule addresses each substance as included or not included.
  • FDA's own scientific review pointed the other way. The agency's Center for Drug Evaluation and Research had recommended against adding these peptides to the 503A bulks list. The HHS enforcement policy sits alongside that recommendation rather than reversing it.
  • It is interim and revocable. HHS has described the policy as interim and has indicated it may revisit the position if safety signals or product quality concerns emerge. A policy that can be withdrawn is not a stable legal foundation.
  • It does not cover research-use-only material. The policy does not extend to research-use-only substances and does not change their regulatory status. Material labeled "research use only" is not for human use, and HHS framed the policy as a way to discourage its continued widespread use.
  • It does not cover 503B outsourcing facilities. Facilities registered under section 503B operate under a different statutory scheme and are not given enforcement discretion by this policy.
  • It has no effect outside the United States. It is a US federal enforcement position. It does not bind the EMA, Health Canada, the MHRA, the TGA or any national medicines agency, and it does not make import of KPV lawful anywhere.

There is also an anti-doping dimension that regulation does not touch. Competitive athletes remain subject to the rules of their sport regardless of how a product was obtained, and a compounded preparation is not an exemption. For the broader jurisdictional picture, see are peptides legal.

What should you ask a clinician and a pharmacy?

If a clinician raises KPV, the policy itself supplies a set of concrete, answerable questions. None of them require technical expertise to ask, and the answers reveal quickly whether a product sits inside the enforcement position.

Questions for the prescribing clinician:

  • What is the clinical reasoning, given that KPV has no FDA approval and no approved indication?
  • What human evidence exists for this specific use, as opposed to animal work?
  • What are the known and unknown risks, and what would prompt stopping?
  • How will this interact with my existing medications and conditions?
  • Has a valid patient-specific prescription been written in my name, as section 503A requires?
  • What approved alternatives exist for my condition, and why are they not being used first?

Questions for the compounding pharmacy:

  • Are you a state-licensed 503A pharmacy, and is the preparation being made under the October 2026 HHS enforcement discretion policy?
  • Who is the original manufacturer of the KPV acetate, is it registered with FDA and CGMP compliant, and does the certificate of analysis identify its physical manufacturing facility location?
  • May I see the certificate of analysis for the lot used, and does its testing align with Appendix B?
  • Does the product contain a single active ingredient, with nothing else added?
  • Is the form topical or oral, consistent with what the policy describes for KPV?
  • For an oral preparation, what human bioavailability documentation do you hold for this exact formulation?
  • Will the label carry the statement "This is a compounded drug product. Not for resale."?
  • How do you report serious adverse events and product quality issues to MedWatch and to the states, and how should I report a problem myself?

A pharmacy operating inside the policy should be able to answer each of these from its own records. Hesitation on the sourcing questions in particular is informative, since those conditions are documentary and either exist in a file or do not.

Medical disclaimer: this article is educational and describes a regulatory position only. It contains no instructions for use and is not medical advice. KPV is not approved for human use by the FDA or by any other major medicines agency. Any decision involving an unapproved substance should be made with a qualified healthcare professional who knows your medical history.

Recommended products

Research peptides selected for quality and purity:

🏆

Where to buy this peptide?

We analyzed the best suppliers to help you find a quality, lab-tested product.

See our selection →

Test your knowledge

Quick quiz · 6 questions

Frequently Asked Questions

Is KPV approved by the FDA in 2026?
No. KPV has no FDA approval. There is no approved KPV product, no FDA-approved labeling and no approved indication in the United States. The October 2026 HHS announcement is an enforcement discretion policy, which describes how the department intends to use its enforcement resources during an interim period. It is not a finding that KPV is safe or effective, and it is not an addition to the section 503A bulks list.
Does the HHS policy make KPV legal to order online for personal use?
No. The policy describes compounding by a state-licensed pharmacy, a federal facility or a licensed physician, under a valid prescription for an identified individual patient, with every listed condition satisfied. It does not extend to research-use-only material and does not change its regulatory status. HHS in fact framed the policy as a way to discourage the widespread use of research-use-only peptides from foreign manufacturers, which it described as a safety risk to US patients.
Can a US pharmacy compound an injectable KPV preparation under this policy?
The policy identifies KPV acetate with topical and oral routes of administration. It does not describe an injectable route for this peptide, which is a notable difference from several of the other listed substances. A compounded injectable KPV preparation therefore falls outside the enforcement position as written. The policy also permits only an FDA 510(k)-cleared syringe as a co-packaged delivery device, which on a plain reading excludes pens and auto-injectors.
Does the policy apply to 503B outsourcing facilities?
No. The enforcement discretion policy addresses compounding under section 503A and does not independently extend to outsourcing facilities registered under section 503B. Those facilities operate under a separate statutory framework with its own requirements, including a different bulk drug substances list. A 503B facility cannot rely on this policy as a basis for using these peptide bulk drug substances.
How long will this enforcement policy last?
It is described as interim. The policy exists while FDA conducts rulemaking on the section 503A bulks list, and the enforcement position is described as remaining in effect until each peptide bulk drug substance is addressed in a final rule as included or not included on that list. HHS has also indicated it may revisit the policy if safety signals or product quality concerns emerge. The Federal Register notice of October 30, 2026 opened a public comment period under docket HHS-OASH-2026-0496 running through November 13, 2026.
Does this policy change anything outside the United States?
No. It is a United States federal enforcement position published by HHS and has no legal effect in other countries. It does not bind the European Medicines Agency, Health Canada, the MHRA, the TGA or any other national medicines authority, and it does not authorize import or personal possession anywhere outside the United States. Rules on unapproved substances vary considerably by jurisdiction, and a US enforcement policy is not a defense under foreign law.

Sources

  1. U.S. Department of Health and Human Services (2026). 503A Peptide Enforcement Discretion Policy, Appendix B: Peptide Identities and Justifications. HHS. (hhs.gov)
  2. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Docket No. HHS-OASH-2026-0496). Federal Register, Vol. 91, No. 209. (federalregister.gov)
  3. U.S. Food and Drug Administration (2026). Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA, Human Drug Compounding. (fda.gov)
  4. U.S. Food and Drug Administration (2026). MedWatch: The FDA Safety Information and Adverse Event Reporting Program. FDA. (fda.gov)
  5. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1):166-178 (PMID 18061177). (PubMed)
  6. Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases (PMID 18092346). (PubMed)
  7. National Center for Biotechnology Information (2026). MSH (11-13), L-Lysyl-L-prolyl-L-valine, CID 125672. PubChem Compound Summary. (pubchem.ncbi.nlm.nih.gov)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer